Identification Of Novel Treatment Strategies For Human Cancers Through Integrative Phosphoproteomics And Kinomics.
Funder
National Health and Medical Research Council
Funding Amount
$763,409.00
Summary
This proposal aims to use new cutting-edge techniques to characterize, at a global level, changes in growth regulatory signals in cancer cells. This will identify proteins critical for cancer growth that represent potential targets for therapy. In addition it will highlight ways to select the most effective treatments for individual patients. The ultimate outcome of this work will be improved treatment strategies for cancer patients, and hence reduced morbidity and mortality.
Protein tyrosine phosphatases (PTPs) control cell communication networks referred to as cellular signaling. This proposal is focused on understanding the roles of PTPs in cellular signaling networks perturbed in human disease & delineating novel opportunities for therapeutic intervention
Mechanisms Of Regulation Of Ribosome Biogenesis And Function In Health And Disease
Funder
National Health and Medical Research Council
Funding Amount
$631,010.00
Summary
The PI3K/AKT signalling pathway drives many cancers and until recently was thought to do so by preventing cancer cell death. We have shown this pathway also regulates the synthesis of ribosomes, the cellular “factories” that make protein and by interfering with PI3K/AKT regulated ribosome synthesis, can kill cancer cells. We aim to establish the mechanisms underlying this regulation of ribosome synthesis and to test the hypothesis that ribosome biogenesis is a novel target for cancer treatment.
Biosensor Imaging In Preclinical Pancreatic Cancer Targeting: Taking Cancer Targeting To New Dimensions.
Funder
National Health and Medical Research Council
Funding Amount
$640,210.00
Summary
Using cutting-edge imaging technology and 3D models that mimic cancer, we can map areas of poor drug response within distinct 'stages' or regions of tumours. Here, we pinpoint and specifically target key factors limiting efficient drug response in order to improve the encouraging anti-cancer profile of new or current drugs in pancreatic cancer.
The regulation to early T cell signalling is a critical step in immune responses. Superimposed onto the biochemical pathways is a spatial organization that defines the immunological synapse. My research aims to map the principles of the spatial organization on the molecular scale to identify how lipids could unbalance the dynamic signalling equilibrium, for example in obese patients. To achieve this goal, my research group has developed single molecule microscopy approaches.
I am a matrix biologist determining the molecular mechanisms and novel therapeutic targets for fibrosis (tissue scarring). In particular, my research, which has a strong translational focus, is involved with elucidating the anti-fibrotic potential of the relaxin peptide-hormones (either alone or as an adjunct therapies to existing/other novel treatments) – as a means of developing therapeutic strategies for the treatment of cardiac and renal fibrosis.
Overcoming Resistance Of Human Metastatic Melanoma To Treatment
Funder
National Health and Medical Research Council
Funding Amount
$727,758.00
Summary
Melanoma is a major Australian health problem, but there is no curative treatment once the disease spreads beyond the skin. I have been working on “overcoming resistance of melanoma to treatment” continuously for 10 years. My past research has provided a number of insights into the resistance of melanoma to treatment. I wish to extend my work to find new treatment approaches against the disease. If successful, this work will greatly benefit melanoma patients and Australian people.
Relaxin family peptides are small proteins that have numerous essential biological roles in the vascular system, brain and gut. The hormone relaxin is currently in Phase III clinical trials to treat heart failure and the other peptides show great potential as drugs to treat diseases including mental illnesses and obesity. My research focuses on developing drugs targeting the receptors for these important peptide systems and understanding how these drugs can be best used therapeutically
The overall goal of the program is to develop novel approaches to slow the progress or prevent neurodegeneration in patients with rare human genetic disorders. The second program is designed to develop novel therapeutics from snake venom proteins. These include proteins with anti-bleeding activity and those with application in wound healing. The third program involves the development of novel biomarkers for the early detection and prognosis in prostate cancer.